Summarized by Masters of Longevity from Longevity Technology.
Report on a licensing collaboration that brings a misfolded-protein seed amplification assay into a German lab to support European neurodegenerative trials.
Key Takeaways
- Amprion licensed its seed amplification assay methodology to MLM Medical Labs for in-house validation and testing in Germany.
- The assay previously received FDA Breakthrough Device Designation and has been commercially available in the US since 2021.
- Amprion launched SAA Protein Manufacturing, LLC to produce standardized protein substrates for wider global testing consistency.
